ASX:EIQ

ASX Biggest Losers

Here are the ASX-listed companies with the biggest losses on Friday.4DMedical (ASX:4DX): -8%, AU$4.25ResMed (ASX:RMD): -6%, AU$29.55EchoIQ (ASX:EIQ): -6%, AU$1.46Phylogica (ASX:PYC): -5%, AU$2.02DroneShield (ASX:DRO): -5%, AU$2.16EQ Resources (ASX:EQR): -5%, AU$0.31Block(ASX:XYZ): -4%, AU$113.35Zip (ASX:ZIP): -4%, AU$2.84Brazilian Rare Earths (ASX:BRE): -4%, AU$4.30Macmahon Holdings (ASX:MAH): -3%, AU$1.00

Echo IQ Advances US Rollout of AI Platform in June Quarter

Echo IQ (ASX:EIQ) advanced the US rollout of its artificial intelligence-driven EchoSolv platform in the three-month period ended June 30, according to a Monday filing with the Australian bourse.The company secured a binding heads of agreement with Pro Medicus (ASX:PME), establishing the framework for a proposed strategic investment of up to AU$20 million and a commercial reseller partnership across the US, the filing said.The company also secured a data licensing deal with Advara HeartCare, per the filing.Echo IQ shares rose nearly 2% in midday trade Monday, while Pro Medicus shares were down nearly 1%.

Echo IQ Secures Data Licensing Deal With Cardiology Services Company

Echo IQ (ASX:EIQ) secured a definitive exclusive data licensing agreement with Advara HeartCare, according to a Thursday filing with the Australian bourse.The agreement, which is for an initial three-year term with an option to extend for another three years, provides the company access to between 500,000 and 1 million de-identified echocardiography studies and associated relevant clinical datasets, the filing said.Financial terms were not disclosed.

Echo IQ to Raise AU$110 Million Via Institutional Placement

Echo IQ (ASX:EIQ) received commitments from existing and new Australian as well as international institutional investors to raise around AU$110 million via a share placement, according to a Wednesday Australian bourse filling.The placement will result in the issue of 75.9 million new fully paid ordinary shares to institutional investors under the firm's available placement capacity, at a price of AU$1.45 per new share.The company will use the proceeds to accelerate the execution of its commercial strategy and support the expansion and deployment of its EchoSolv platform across the US, as well as to fast-track the development of its broader cardiovascular artificial intelligence platform.

Bell Potter Starts Echo IQ at Buy with AU$1.65 Price Target

Australian Shares Retreat; Judo Capital Holdings Cuts Fiscal 2026 Profit Before Tax Guidance

Australian shares declined on Thursday after investors reacted to a continued fall in oil prices as supply concerns eased.The S&P/ASX 200 Index fell 0.68%, or 59.70 points, to close at 8,748.70.Oil prices are reaching pre-war levels as tankers transit through the Strait of Hormuz. Brent crude oil futures fell to around $72 per barrel. Meanwhile, gold fell below $4,000 for the first time since November 2025.On the domestic front, Australia's seasonally adjusted unemployment rate fell to 4.4% in May from 4.5% in April, data from the Australian Bureau of Statistics (ABS) showed.Australia's total household wealth rose 1.2% to AU$19.212 trillion in the March quarter due to growth in land and dwelling values, according to figures released by ABS.Australian total household spending in May was AU$80.64 billion on a current price, seasonally adjusted basis, rising 5.5% year-over-year and 1.3% month-on-month, according to data from the ABS.Seasonally adjusted job vacancies in Australia fell 2.1% to 329,500 in the three months to May, ABS said.In company news, Judo Capital Holdings (ASX:JDO) said it now expects a fiscal 2026 profit before tax of AU$163 million to AU$169 million. The cut comes as Judo now expects its fiscal year cost of risk to be in the range of AU$116 million to AU$122 million, reflecting an increase in certain provisions driven mainly by three exposures across different sectors that recently emerged due to "customer-specific developments." Its shares dropped nearly 38% on close, earlier reaching their lowest point in over two years.Worley (ASX:WOR) increased its expected fiscal 2026 underlying earnings before interest, taxes, and amortization (EBITA) impact to up to AU$60 million, up from a prior estimate of AU$30 million to AU$40 million, due to ongoing Middle East project delays.Lastly, Pro Medicus (ASX:PME) will provide an investment of up to AU$20 million to Echo IQ (ASX:EIQ) and become a reseller of the EchoSolv product suite across the US under a proposed commercial partnership.

Pro Medicus to Make Up to AU$20 Million Debt Investment in Echo IQ as Part of Proposed Commercial Partnership

Pro Medicus (ASX:PME) will provide an investment of up to AU$20 million to Echo IQ (ASX:EIQ) and become a reseller of the EchoSolv product suite across the US under a proposed commercial partnership, according to a Thursday filing with the Australian bourse.Subject to definitive documentation, Pro Medicus will initially invest AU$10 million and will have an option to invest an additional AU$10 million upon Echo IQ receiving US Food and Drug Administration clearance for its EchoSolv HF software.Under the agreed framework, both the initial and subsequent investment will be made through a subscription for secured convertible notes, per the filing.The US FDA submission for EchoSolv HF "remains on track for an expected outcome in the near term," Echo IQ said.

Echo IQ Appoints CFO

Echo IQ (ASX:EIQ) appointed Matthew Dodds as chief financial officer, effective Wednesday, according to a Tuesday filing with the Australian bourse.Dodds most recently served as senior vice president of corporate development and information technology at LivaNova, the filing added.

Update: Echo IQ Enters Collaboration With Mayo Clinic to Evaluate AI-Based Cardiac Risk Stratification in Cancer Patients, Shares Down 4%

(Updates to add stock movement in the headline and the last paragraph)Echo IQ (ASX:EIQ) struck a research collaboration agreement with Mayo Clinic to evaluate the ability of Echo's proprietary artificial intelligence platform to estimate cardiac risk in cancer patients, according to a Friday filing with the Australian bourse.The research will assess the platform's ability to generate predictive risk scores for heart failure based on echocardiogram data for oncology patients.The study will also aim to assess the applicability of the AI platform in a "large and clinically important patient population beyond its current cardiovascular applications," the company said.The company's shares fell 4% in recent Friday trade.

Echo IQ Enters Collaboration With Mayo Clinic to Evaluate AI-Based Cardiac Risk Stratification in Cancer Patients

Echo IQ (ASX:EIQ) struck a research collaboration agreement with Mayo Clinic to evaluate the ability of Echo's proprietary artificial intelligence platform to estimate cardiac risk in cancer patients, according to a Friday filing with the Australian bourse.The research will assess the platform's ability to generate predictive risk scores for heart failure based on echocardiogram data for oncology patients.The study will also aims to assess the applicability of the AI platform in a "large and clinically important patient population beyond its current cardiovascular applications," the company said.

Echo IQ Says EchoSolv AS Software Usage Up Around 131%

Echo IQ (ASX:EIQ) said the usage of EchoSolv AS, its decision support software for the assessment of severe aortic stenosis, a progressive heart condition, was up around 131% quarter over quarter in the three months ended March 31, according to a Thursday Australian bourse filing.The company said 9,220 echocardiograms were processed in the first quarter, from 3,992 in the December 2025 quarter.The company is progressing its heart failure clinical decision support product, EchoSolv HF, through the US Food and Drug Administration 510(k) pathway.It is also focused on securing major US hospital group signings and advancing regulatory clearance via Australia's Therapeutic Goods Administration, per the filing.Echo IQ's shares fell nearly 2% in recent trading on Thursday.

Echo IQ Deploys AI-Based Decision Support Software into the US Health System

Echo IQ (ASX:EIQ) deployed EchoSolv AS, its artificial intelligence-based decision support software for the assessment of severe aortic stenosis, into the Mount Sinai Health System in New York, according to a Tuesday filing with the Australian bourse.The company continues to engage with prospective hospitals in the US regarding potential opportunities for the product, the filing said.